Ceftobiprole medocaril

Research use only, not for human use.

Ceftobiprole medocaril is the parenteral prodrug of Ceftobiprole. Ceftobiprole is a broad-spectrum cephalosporin with activity against Methicillin-resistant staphylococcus aureus (MRSA).

Ceftobiprole medocaril is the parenteral prodrug of Ceftobiprole. Ceftobiprole is a broad-spectrum cephalosporin with activity against Methicillin-resistant staphylococcus aureus (MRSA).(In Vivo):Ceftobiprole medocaril (10, 40, 160 mg/kg; single dose; sc) has T 1/2 s from 20 min to 31 min, as the dose rose from 40 mg/kg to 160 mg/kg. The AUC/dose values for the escalating single doses ranges from 0.585 to 1.33, and the C max /dose values decreases from 1.08 to 0.90 in neutropenic thigh-infected mice .

——

Ceftobiprole medocaril (BAL5788; s.c.; 3 × q12h; total daily doses of BAL9141 equivalents, 2.1, 4.2, or 8.4 mg/kg) causes ten-day cumulative survival rates ranged from 57 to 100% for female Swiss albino mice (body weight, 20 to 22 g) infected Penr Cros Ctxs strain P-15986. Ceftobiprole medocaril (10, 40, 160 mg/kg; single dose; sc) has T1/2s from 20 min to 31 min, as the dose rose from 40 mg/kg to 160 mg/kg. The AUC/dose values for the escalating single doses ranges from 0.585 to 1.33, and the Cmax/dose values decreases from 1.08 to 0.90 in neutropenic thigh-infected mice.

BAL5788

GPCR/G Protein

Antibacterial

——

——

——

376653-43-9

690.66

C26H26N8O11S2

>98% (HPLC)

——

CC(O1)=C(COC(N(CC2)C[C@@H]2N(CC/C2=C\C(CS[C@@H]3[C@@H]4NC(/C(/c5nsc(N)n5)=N\O)=O)=C(C(O)=O)N3C4=O)C2=O)=O)OC1=O

——

(-20℃)

With Ice Pack

≥ 2 years